Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Phase 3 N=41 Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
B-Cell Non Hodgkin Lymphoma
Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Phase 2 N=51 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022
Phase 2 N=45 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Diffuse Large B-Cell Lymphoma · Transformed Follicular Lymphoma · Mantle Cell Lymphoma
Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants
Phase 3 N=849 Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005
Phase 2 N=50 Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 34.7 percentage of participants
Phase 2 N=13 Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants
Phase 2 N=22 PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 20 participants
Phase 2 N=38 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma
Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=134 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Phase 2 N=14 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Phase 2 N=60 R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
N/A N=158 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants
Phase 2 N=67 Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Leukemia · Lymphoma
Primary: Objective Response Rate — 2; 4; 6; 17 Participants
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=60 A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Primary: ORR — 13 Participants
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Phase 2 N=20 Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Lymphoma · B-cell Non-Hodgkin's Lymphoma
Primary: Improve the Overall Response Rate — 4; 2; 7; 4 participants
Phase 2 N=39 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Complete Response (CR) Rate — 0; 36 percent of participants
Phase 3 N=312 Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Diffuse Large B-cell Lymphoma · de Novo DLBCL · DLBCL Transformed From Indolent Lymphoma
Primary: Progression Free Survival (PFS) — 7.3; 6.3 Months
Phase 2 N=50 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Follicular Lymphoma · Marginal Zone B-Cell Lymphoma · MALT Lymphoma
Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants
Phase 2 N=21 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Phase 2 N=20 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Phase 2 N=10 Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
Relapsed/Refractory Aggressive B-cell Lymphomas
Primary: Maximum Tolerated Dose (MTD) of MEDI-551 — NA; NA mg/kg
Phase 3 N=322 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
Phase 2 N=8 Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent High Grade B-Cell Lymphoma · Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I) — 0; 1; 2; 0 Participants
Phase 2 N=81 Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Lymphoma, Large-Cell, Diffuse
Primary: Number of Participants With Objective Response — 9 participants